Michael Axelson is currently the VP of Clinical Development at Eli Lilly and Company, where they oversee clinical trial designs and initiatives in immuno-oncology. With extensive experience in hematology and oncology, Michael previously held leadership roles at Tempus, Inc. and Bristol-Myers Squibb, focusing on oncology strategies in the Asia-Pacific region. They also served as a Medical Officer at the FDA, contributing to the review and approval of over 100 INDs and 8 approved drugs. Michael began their medical career after completing a Doctor of Medicine (MD) at the University of Michigan Medical School and a fellowship in Hematology & Medical Oncology at UT Southwestern Medical Center.
This person is not in the org chart
This person is not in any teams
This person is not in any offices